Table 2. Analysis of variance of model response to drug effects.
| Simulated drug effect | F value | p value | |
| alpha2 | 0.01 | 0.916 | |
| AMPA gmax | 1.76 | 0.185 | |
| AMPA τ2 | 25.14 | 6.00E-07 | * |
| NMDA | 21.17 | 4.55E-06 | * |
| CR proj | 0.35 | 0.554 | |
| alpha2:AMPA gmax | 0.92 | 0.338 | |
| alpha2:AMPA τ2 | 1.23 | 0.268 | |
| AMPA gmax:AMPA τ2 | 13.43 | 2.56E-04 | * |
| alpha2:NMDA | 6.52 | 0.011 | |
| AMPA gmax:NMDA | 5.24 | 0.022 | |
| AMPA τ2:NMDA | 0.01 | 0.914 | |
| alpha2:CR proj | 1.78 | 0.182 | |
| AMPA gmax:CR proj | 10.44 | 0.001 | |
| AMPA τ2:CR proj | 68.18 | 3.29E-16 | * |
| NMDA:CR proj | 1.91 | 0.167 | |
| alpha2:AMPA gmax:AMPA τ2 | 0.84 | 0.358 | |
| alpha2:AMPA gmax:NMDA | 0.48 | 0.490 | |
| alpha2:AMPA τ2:NMDA | 1.53 | 0.217 | |
| AMPA gmax:AMPA τ2:NMDA | 1.57 | 0.211 | |
| alpha2:AMPA gmax:CR proj | 0.37 | 0.545 | |
| alpha2:AMPA τ2:CR proj | 4.19 | 0.041 | |
| AMPA gmax:AMPA τ2:CR proj | 1.11 | 0.292 | |
| alpha2:NMDA:CR proj | 2.69 | 0.101 | |
| AMPA gmax:NMDA:CR proj | 4.21 | 0.040 | |
| AMPA τ2:NMDA:CR proj | 13.34 | 2.70E-04 | * |
*
p < 0.001
Using the wellness metric (see text), as the outcome variable, 97 of 1,500 simulated medications produced non-zero values. ANOVA of this output, using parameters for drug effects as factors, is shown. Highly significant effects (p < 0.001) are indicated. CR proj = CR+ projection.